Obinutuzumab

Adding obinutuzumab to standard therapy for active lupus nephritis led to significantly higher rates of complete renal response, according to data published in The New England Journal of Medicine.

In this video, Iberia Romina Sosa, MD, PhD, discusses the results of a study presented at ASH Annual Meeting and Exposition, which examined the use of obinutuzumab in patients with thrombotic thrombocytopenic purpura.

SAN DIEGO — A multidrug combination significantly improved survival for certain patients with leukemia compared with standard chemoimmunotherapy, according to results of the randomized phase 3 AMPLIFY study.

SAN DIEGO — Obinutuzumab and ianalumab are two promising B-cell depleting therapies on the horizon for lupus, according to data presented at the 2024 Congress of Clinical Rheumatology West.

Ongoing research into the disease processes of lupus has yielded an increased number of therapeutic targets, according to a presenter at the 2024 Association of Women in Rheumatology annual conference.

Fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, improved survival compared with standard chemoimmunotherapy for certain adults with leukemia, according to a topline data announcement.

In a video interview, Matthew Cortese, MD, MPH, discusses how AI could transform the treatment landscape for CLL.

In a video interview, Matthew Cortese, MD, MPH, discusses the importance of long-term monitoring in CLL care.

In a video interview, Matthew Cortese, MD, MPH, discusses strategies to combat infections in CLL patients.

In a video interview, Matthew Cortese, MD, MPH, discusses advances in treatments for relapse/refractory CLL.